| Title | JinqiJiangtang tablets for prediabetes: A randomized, double-blind and placebo-controlled clinical trial |
| Authors | Wang, Hui Guo, Liping Shang, Hongcai Ren, Ming Wang, Xuemei Wang, Dehui Chen, Jianzong Li, Shuanglei Chen, Liming Wang, Yue Liu, Zhi Zhai, Jingbo Song, Yuzhen Cao, Hongbo Zhang, Junhua Liu, Chunxiang Sun, Xiao Huo, Da Mu, Wei Zhang, Li Zheng, Wenke Yan, Xiaoyan Yao, Chen |
| Affiliation | Tianjin Univ Tradit Chinese Med, Inst Tradit Chinese Med, Evidence Based Med Ctr, 312 Anshan Western Rd, Tianjin 300193, Peoples R China. Beijing Univ Chinese Med, Dongzhimen Hosp, Minist Educ & Beijing, Key Lab Chinese Internal Med, Beijing 100700, Peoples R China. Peking Univ, Hosp 1, Dept Integrated Chinese & Western Med, Xishiku St, Beijing 100034, Peoples R China. Tianjin Univ TCM, Affiliated Hosp 2, Dept Endocrinol, Zhenli St, Tianjin 300150, Peoples R China. Xijing Hosp, Dept TCM, Changlexilu St, Xian 710032, Shaanxi, Peoples R China. Guangxi Coll TCM, Dept Endocrinol, Affiliated Hosp 1, Yuanhu St, Nanning 530023, Peoples R China. Tianjin Med Univ, Metab Dis Hosp, Dept Endocrinol, Pingjiang St, Tianjin 300211, Peoples R China. Inner Mongolia Peoples Hosp, Zhaowudast, Hohhot 010017, Peoples R China. Tangshan Chinese Med Hosp, Kang Zhuang St, Tangshan 063000, Peoples R China. Peking Univ, Clin Inst, Xishiku St, Beijing 100034, Peoples R China. Tianjin Univ Tradit Chinese Med, Inst Tradit Chinese Med, Evidence Based Med Ctr, 312 Anshan Western Rd, Tianjin 300193, Peoples R China. Shang, HC (reprint author), Beijing Univ Chinese Med, Dongzhimen Hosp, Minist Educ & Beijing, Key Lab Chinese Internal Med, Beijing 100700, Peoples R China. |
| Keywords | IMPAIRED GLUCOSE-TOLERANCE TYPE-2 DIABETIC-PATIENTS BERBERINE SECRETION MEDICINES RISK RATS |
| Issue Date | 2017 |
| Publisher | SCIENTIFIC REPORTS |
| Citation | SCIENTIFIC REPORTS.2017,7. |
| Abstract | This study observed the efficacy and safety of JinqiJiangtang tablets (JQJT tablets, a traditional Chinese patent medicine) for pre-diabetes. Four hundred patients with pre-diabetes at five centres were treated for 12months and followed for an additional 12months to investigate the preventative effects of JQJT tablets (Registration ID: ChiCTR-PRC-09000401). The incidence rate of diabetes mellitus was the primary endpoint. The risk of converting from pre-diabetes to diabetes was 0.58-fold less in the JQJT tablets group than in the placebo group [HR (95% CI): 0.58 (0.384, 0.876), P = 0.010]. Furthermore, the probability of achieving normalized blood glucose was 1.41-fold greater in the JQJT tablets group than in the placebo group [HR (95% CI): 1.41 (1.002, 1.996), P = 0.0049]. ITT analysis revealed that the incidence of diabetes upon treatment completion was 16.5% in the JQJT tablets group compared with 28.9% in the control group. The percentage of patients with normalized blood glucose upon 12-month intervention was 41.8% in the JQJT tablets group compared with 27.8% in the control group. JQJT tablets could be an effective intervention for preventative treatment of Type 2 diabetes mellitus. |
| URI | http://hdl.handle.net/20.500.11897/462319 |
| ISSN | 2045-2322 |
| DOI | 10.1038/s41598-017-11583-5 |
| Indexed | SCI(E) |
| Appears in Collections: | 第一医院 |
